Viewing Study NCT04675333


Ignite Creation Date: 2025-12-25 @ 2:41 AM
Ignite Modification Date: 2025-12-30 @ 11:24 PM
Study NCT ID: NCT04675333
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-08-03
First Post: 2020-12-15
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
Sponsor: ALX Oncology Inc.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module